« Back
Home /
Tubeimoside I

Tubeimoside I

Item no.	HY-N0890-50mg
Manufacturer	MedChem Express
CASRN	102040-03-9
Amount	50 mg
Quantity options	10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Colorectal Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Jiang SL, et al. Tubeimoside-1, a triterpenoid saponin, induces cytoprotective autophagy in human breast cancer cells in vitro via Akt-mediated pathway. Acta Pharmacol Sin. 2019 Jul;40(7):919-928.\|[2]Wang K, et al. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. Cell Death Dis. 2020 Aug 26;11(8):708.\|[3]Feng X, et al. Tubeimoside I induces accumulation of impaired autophagolysosome against cervical cancer cells by both initiating autophagy and inhibiting lysosomal function. Cell Death Dis. 2018 Nov 2;9(11):1117.\|[4]Xu Y, et al. Multiple pathways were involved in tubeimoside-1-induced cytotoxicity of HeLa cells. J Proteomics. 2011 Dec 21;75(2):491-501. \|[5]Yang JB, et al. Tubeimoside-1 induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells in vitro. Acta Pharmacol Sin. 2016 Jul;37(7):950-62.\|[6]Wang Y, et al. Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma (HepG2) cells. Biol Pharm Bull. 2011;34(6):831-8.\|[7]Wu Q, et al. Tubeimoside-1 attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models. Immunopharmacol Immunotoxicol. 2013 Aug;35(4):514-23. \|[8]Zhang JB, et al. Tubeimoside I attenuates inflammation and oxidative damage in a mice model of PM2.5-induced pulmonary injury. Exp Ther Med. 2018 Feb;15(2):1602-1607. \|[9]Luo M, et al.Tubeimoside I improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression. Biomed Pharmacother. 2020 Jun;126:110083.\|[10]Wu T, et al. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. J Ethnopharmacol. 2025 Jan 10;336:118754. \|[11]Yang X, et al. Tubeimoside I promotes angiogenesis via activation of eNOS-VEGF signaling pathway. J Ethnopharmacol. 2021 Mar 1;267:113642.
Smiles	C[C@@]12C([C@@]3([H])[C@](C(O[C@@H]4OC[C@H](O)[C@H](O)[C@H]4O[C@@H]5O[C@@H](C)[C@H](OC(C[C@](O)(C)CC6=O)=O)[C@@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]5O)=O)(CCC(C)(C)C3)CC2)=CC[C@@]8([H])[C@@]1(C)CC[C@]([C@](C)(CO)[C@H]9O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O[C@@H]%11OC[C@H](O6)[C@H](O)[C@H]%11O)([H])[C@]8(C)C[C@@H]9O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Tubeimoside-1,Lobatoside-H
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Akt; Autophagy; HSP; Interleukin Related; NF-κB; p38 MAPK; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	1319.43
Product Description	Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases[1][2][3][4][5][6][7][8][9][10][11].
Manufacturer - Research Area	Cancer; Inflammation/Immunology; Cardiovascular Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-N0890-50mg-safety-datasheet.pdf